Theravance Biopharma (TBPH) Equity Average (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Equity Average data on file, last reported at $293.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $293.7 million, up 71.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.7 million (up 71.97% YoY), and the FY2025 annual result was $236.1 million, up 21.55% from the prior year.
• Equity Average grew to $293.7 million in Q1 2026 per TBPH's latest filing, from $264.7 million in the prior quarter.
• Over five years, Equity Average peaked at $461.2 million in Q4 2022 and troughed at -$350.6 million in Q2 2022.
• A 5-year average of $175.7 million and a median of $208.9 million in 2024 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 302.46% in 2023 and fell as far as 50.22% in 2023.
• A 5-year view of Equity Average shows it stood at $461.2 million in 2022, then tumbled by 50.22% to $229.6 million in 2023, then slipped by 21.33% to $180.6 million in 2024, then surged by 46.57% to $264.7 million in 2025, then increased by 10.94% to $293.7 million in 2026.
• Business Quant data shows TBPH's Equity Average at $293.7 million in Q1 2026, $264.7 million in Q4 2025, and $228.8 million in Q3 2025.